• Viking Therapeutics recently initiated a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist for obesity, following US FDA clearance of its IND and adding to its expanding metabolic disease pipeline.
• This move, alongside ongoing late-stage development of injectable and planned oral VK2735, signals Viking’s intent to build a differentiated, multi-mechanism obesity franchise spanning both delivery routes.
• We’ll now explore how advancing VK3019 into first-in-human testing could reshape Viking Therapeutics’ investment narrative around obesity treatments.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you have to believe its obesity pipeline can translate late stage VK2735 and earlier VK3019 programs into future, first meaningful revenue. The VK3019 Phase 1 start broadens the platform, but it does not change that the most important near term catalyst remains successful VANQUISH Phase 3 readouts for VK2735, while the biggest risk is continued heavy cash burn without any commercial product to offset losses.

Among recent announcements, the ongoing VANQUISH Phase 3 trials for injectable VK2735 are most relevant here, as VK3019 now sits alongside them in obesity. Together, they frame a dual track story where late stage VK2735 data, plus future VK3019 readouts, could both reinforce or challenge the idea that Viking’s multi asset obesity franchise can eventually overcome its current pre revenue status.

Yet behind the excitement around VK3019, investors should still be aware of the risk that prolonged, high R&D spend without revenue could...

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This implies an increase of about $372.5 million in earnings from -$359.6 million today.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 135% upside to its current price.

Exploring Other Perspectives

Before this VK3019 news, the most bullish analysts were already assuming about US$497.5 million of revenue by 2029, which is far more optimistic than consensus and depends heavily on VK2735 plus the broadening obesity pipeline, so it is worth asking whether this new trial supports that view or makes you more cautious about the balance of risk and reward.

Explore 12 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 42 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.